Media stories about Columbia Laboratories (NASDAQ:JNP) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Columbia Laboratories earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 45.314104879015 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of JNP traded up $0.10 during mid-day trading on Monday, hitting $10.50. The stock had a trading volume of 30,417 shares, compared to its average volume of 98,709. The firm has a market cap of $114.14, a PE ratio of -68.60 and a beta of 0.46. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.20 and a quick ratio of 1.81. Columbia Laboratories has a 52 week low of $3.65 and a 52 week high of $13.25.
Columbia Laboratories (NASDAQ:JNP) last issued its earnings results on Thursday, March 8th. The specialty pharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.22. The firm had revenue of $11.79 million for the quarter, compared to analyst estimates of $16.00 million. Columbia Laboratories had a negative return on equity of 3.91% and a negative net margin of 4.12%. sell-side analysts anticipate that Columbia Laboratories will post 3.5 earnings per share for the current fiscal year.
About Columbia Laboratories
Juniper Pharmaceuticals, Inc, a women's health therapeutic company, focuses on developing therapeutics that address unmet medical needs in women's health. The company develops its products using its drug delivery technologies, including bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa for sustained and controlled delivery of active drug product; and a novel intra-vaginal ring (IVR) technology.
Receive News & Ratings for Columbia Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Columbia Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.